Scientific Differentiation
Why the platform works
The six-stage journey isn't just process for its own sake: each stage produces evidence a licensing partner can evaluate on the same terms regulators already use.
Why it works
A more water-loving molecule
Conjugating the API with a BOM makes the resulting molecule far more polar, so it binds water more readily. That single change is what unlocks the solubility gains across every drug we've tested. And because excipients are removed rather than added, the resulting rAPI is simpler to manufacture than a traditional formulation.
Enhanced solubility
Up to a 600× increase
Across our pilot NSAID molecules, rAPIs show a 102 to 103-fold increase in aqueous solubility compared to the parent API. For diclofenac, the two candidate BOM conjugates lifted solubility 600× and 325× over the unmodified drug.
Faster dissolution
Minutes, not hours
Where the parent API can take close to two hours to fully dissolve, our rAPIs get there in around 20 minutes, a direct route to a quicker onset of action. That also opens the door to delivery formats a poorly soluble drug can't support today, like oral solutions and fast-acting injectables.
Improved in-vivo performance
Pharmacological Evidence
In-vivo studies show our rAPIs reach the bloodstream faster and at higher concentrations than the parent drug, consistent with a faster, more predictable effect in the body. That's the kind of result that matters most to a licensing partner, since it's measured the same way regulators already evaluate a drug.
Expanding The Platform
From pilot molecules to life-saving drugs
Pilot work on a class of NSAIDs (aspirin, paracetamol, diclofenac, and ibuprofen) proved out the platform: solubility enhanced, preclinical trial performance improved. RapiDrugs is now applying the same rAPI approach to high-impact drugs across therapeutic areas.
Flagship Case Study
Propofol: from oil-based emulsion to clear solution
Marketed propofol is a lipid emulsion made from 10% soybean oil, 2.25% glycerol, and 1.2% egg lecithin, plus EDTA, metabisulfite, and benzyl alcohol. That formulation causes pain on injection, is susceptible to bacterial growth, and can trigger allergic reactions in patients with an egg allergy.
Lipid-free, water-clear
A lipid-free rAPI at ~15 mg/mL
rAPI Propofol is a lipid-free composition with improved solubility of roughly 15 mg/mL, about 110× that of unmodified propofol. It shows no allergic reaction and no bacterial contamination risk, addressing the core failure modes of the marketed emulsion.
Safety, confirmed
Pre-clinical Trials
Preclinical testing shows the rAPI formulation performs safely alongside the parent drug and the marketed emulsion, while reaching the bloodstream faster. Because the lipid emulsion is removed entirely, it also avoids the bacterial growth risk and egg-allergy concerns tied to the marketed version, including in sensitive populations such as geriatric and infant patients.
